Results 301 to 310 of about 180,829 (383)

Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China

Lihong Gao, Hanxiao Zhu, Jia Wang, Yingtao Lin, Baolong Ding, Yuyang Sun, Tiantian Tao, Xin Li   +7 more
openalex   +2 more sources

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

SARS-CoV-2 Chronic Intervillositis: Variations of Maternal Antiviral Response. [PDF]

Am J Reprod Immunol
Kozlova D, Mayer O, Shomron N, Azan Y, Shlayem R, Yegorov Y, Rainy N, Natan A, Tobar AF.   +8 more
europepmc   +1 more source

Risk of persistent hypogammaglobulinaemia in children with autoimmune bullous dermatoses treated with rituximab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
S. Benkimoun, A. Welfringer‐Morin, V. Barlogis, R. Gravier Dumonceau, E. Bourrat, C. Chiaverini, C. Léauté‐Labrèze, P. Joly, B. Tedbirt, A.‐C. Bursztejn, G. Font, C. Bodemer, M.‐A. Richard, S. Mallet, Groupe Bulles of the French Society of Dermatology; Clinical Research Group of the French Society of Pediatric Dermatology   +14 more
wiley   +1 more source

Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study

Cancer Innovation, Volume 5, Issue 2, April 2026.
Compared to conventional chemotherapy, treatment with BV‐AVD ± R in CAYA Hodgkin lymphoma patients resulted in comparable response rates (ORR: 96.4% vs. 95.4%) but with a marked reduction in Grade 4 hematologic toxicity (25.6% vs. 61.2%). BV‐AVD monotherapy yielded a higher ORR than BV‐AVD + R (100% vs. 93.9%).
Mengqing Xie, Meng Yuan, Mengwei Ren, Jing Tian, Shengyu Zhou, Xiaohui He, Yan Qin, Peng Liu, Jianliang Yang, Mengyuan Han, Fei Ma, Sheng Yang, Sidan Li   +12 more
wiley   +1 more source

Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review. [PDF]

Front Med (Lausanne)
Chi C, Wang S, Xu M, Shi Y, Ran X.
europepmc   +1 more source

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors

, 2009
Katy Milne, Martin Köbel, Steven E. Kalloger, Rebecca Barnes, Dongxia Gao, C. Blake Gilks, Peter H. Watson, Brad H. Nelson   +7 more
openalex   +2 more sources

Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options.
Vassiliki Labropoulou, Evgenia Verigou, Eleni P. Kourea, Maria Liga, Dimitrios Tsokanas, Krisela‐Christina Valera, Alexandros Spyridonidis   +6 more
wiley   +1 more source

Unusual upper back presentation of primary cutaneous diffuse large B-cell lymphoma, leg-type with complete regression. [PDF]

JAAD Case Rep
Korytnikova E, Zhou A, Aiudi D, Murphy M, Kerr P.   +4 more
europepmc   +1 more source

Sex differences in genomics, immune microenvironment and immunotherapy response in adult grade 4 gliomas

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Overall survival of patients with brain tumors receiving ICIs treatment Abstract Purpose Sex differences in the prevalence of gliomas have been reported; however, whether there are sex differences in the development and immunotherapy of gliomas remains poorly understood.
Feng Tang, Zhen‐Yuan Liu, Xi Chen, Jin‐Zhou Yang, Zhi‐Qiang Li   +4 more
wiley   +1 more source